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ABSTRACT
Metnase is a human SET and transposase domain
protein that methylates histone H3 and promotes
DNA double-strand break repair. We now show
that Metnase physically interacts and co-localizes
with Topoisomerase IIa (Topo IIa), the key chromo-
some decatenating enzyme. Metnase promotes pro-
gression through decatenation and increases
resistance to the Topo IIa inhibitors ICRF-193 and
VP-16. Purified Metnase greatly enhanced Topo IIa
decatenation of kinetoplast DNA to relaxed circular
forms. Nuclear extracts containing Metnase decate-
nated kDNA more rapidly than those without
Metnase, and neutralizing anti-sera against Met-
nase reversed that enhancement of decatenation.
Metnase automethylates at K485, and the presence
of a methyl donor blocked the enhancement of Topo
IIa decatenation by Metnase, implying an internal
regulatory inhibition. Thus, Metnase enhances
Topo IIa decatenation, and this activity is repressed
by automethylation. These results suggest that
cancer cells could subvert Metnase to mediate clini-
cally relevant resistance to Topo IIa inhibitors.
INTRODUCTION
Transposases mediate DNA movement in lower organ-
isms by excising deﬁned segments of DNA and then
reinserting them at other locations in the genome, a pro-
cess that can be repeated multiple times for a given
segment (1,2). While transposase activity probably
accounts for half of the present organization of the
human genome, almost all of these sequences are pseudo-
genes, as unregulated DNA mobility would be deleterious
to human cells, causing genome instability (1–4).
Recently we identiﬁed and characterized Metnase (also
called SETMAR), a human protein with a transposase
domain derived from Mariner transposons fused to a
SET domain. Metnase is expressed in most tissues, methy-
lates histone H3, promotes foreign DNA integration and
enhances nonhomologous end-joining (NHEJ) of DNA
double-strand breaks (DSBs) (5). Metnase is present
only in primates, and it possesses partial transposase activ-
ity, including sequence-speciﬁc DNA binding, assembly of
paired end complexes, cleavage of the 50-end of the
Mariner terminal inverted repeat and promotion of inte-
gration at a TA dinucleotide target site (6–8).
We found that Metnase has endonuclease activity that
nicks and linearizes but does not degrade supercoiled
DNA (9). Therefore, we postulated that Metnase plays a
role in decatenating DNA. DNA replication results in
intertwined sister chromatids that must be untangled, or
decatenated, to ensure proper chromatid segregation in
mitosis and prevent chromatid breaks during anaphase.
Topoisomerase IIa (Topo IIa) is the critical decatenating
enzyme. It functions by creating transient DSBs through
which it passes a second double-stranded DNA and then
religates the broken ends (10).
In human cells, chromosome catenation status is
actively monitored, and at two points in the cell cycle,
catenated DNA inhibits cycle progression. One decatena-
tion checkpoint prevents progression from G2 to M (11),
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anaphase (12–15). The decatenation checkpoints are
highly conserved in plants and animals and have been
observed in many tissue and cell types (16,17), including
yeast (18). Emerging data indicate that decatenation
checkpoints are impaired in human cancers and in both
embryonic and hematopoietic stem cells (16,19,20). The
decatenation checkpoints are activated when ATM- and
Rad3-related (ATR) senses catenated chromosomes
and then signals through BRCA1 to inhibit cyclin B1
and Cdk1 to halt cell cycle progression toward mitosis
(17,21). In addition, ATR may inhibit PLK1 when chro-
matids remain catenated, thereby preventing progression
to mitosis (21).
While decatenation checkpoint signaling is becoming
clearer, the precise biochemical mechanism of decatena-
tion is less well deﬁned. We report here an interaction
between Metnase and Topo IIa and show that Metnase
promotes Topo IIa decatenation activity and enhances
progression through the metaphase decatenation check-
point in vivo. This enhancement is inhibited by the auto-
methylation of Metnase.
MATERIALS AND METHODS
Immunoprecipitation
Cells were harvested and lysed with radio immuno preci-
pitation assay (RIPA) buﬀer. Protein extracts were
precleared with 40ml of protein A/G beads. Two milli-
grams of protein extract was used for each immunopreci-
pitation. Two microliters of anti-V5 (Invitrogen,
Carlsbad, CA), 2ml of anti-Metnase or 2.5ml of anti-
Topo IIa (Topogen, Port Orange, FL) antibodies was
used in a total volume of 500ml. Lysates were incubated
overnight in 500ml RIPA buﬀer with antibody at 48Ci n
the presence of 1U DNase I. Thirty microliters of protein
A/G beads was added and incubated for 2h at 48C. Beads
were then washed three times with RIPA buﬀer and twice
with phosphate-buﬀered saline (PBS). The beads were
boiled, and samples were run on a SDS–PAGE gel and
analyzed by western blot using appropriate anti-sera.
Input represented 1% of the total lysate for all
experiments.
Manipulating Metnaseexpression
HEK-293 derivatives over-expressing Metnase-V5 were
generated by stably transfecting pcDNA-Metnase (neo-
mycin selectable), and derivatives under-expressing
Metnase were stably transfected with U6-siRNA
Metnase (hygromycin selectable), as described (5).
Controls were transfected with pcDNA or U6 vector
that makes a nonsense siRNA transcript. HEK-293T
cells were stably transfected with the puromycin-selectable
pCAPP-Metnase vector or empty pCAPP. Total Metnase
levels were measured by western blot using anti-Metnase
serum (5). Expression levels were measured before each
experiment to conﬁrm appropriate Metnase expression
levels. Cells with forced under-expression of Metnase
grew more slowly than vector-transduced cells, and this
was controlled for in all experiments.
Metaphasearrest analysis
ICRF-193 (MP Biomedicals, Solon, OH) reversibly inhi-
bits Topo IIa without inducing DNA DSBs, thereby
allowing assessment of the decatenation checkpoint
(11,17,22). ICRF-193 and VP-16 were dissolved in
DMSO and further diluted in growth media. Unsynchro-
nized cells were treated with 10mM ICRF-193, 5mM
VP-16 or equivalent volume of DMSO (vehicle control)
for 4 or 18h, harvested, ﬁxed and stained with an anti-
tubulin antibody and 40-6-diamidino-2-phenylindole
(DAPI, Vectashield). These concentrations were chosen
by dose–response experiments. Interphase cells and cells
at metaphase were counted by immunoﬂuorescence micro-
scopy to assess ICRF-193- and VP16-induced metaphase
arrest. The fractional increase in ICRF-193 or VP-16
metaphase-arrested cells over vehicle controls was due to
failure to traverse the M phase decatenation checkpoint
(12–15). Each experiment was performed at least three
times with 850–1800 cells counted per condition; statistics
were calculated by using t-tests, and standard deviation
(SD) is shown.
Localization of Topo IIaand Metnase
After appropriate treatment, 2 10
4cells were cytospun
onto microscope slides, air dried for 5min at room tem-
perature and ﬁxed in 100% methanol for 10min at  208C.
The remaining steps were carried out at room tempera-
ture. Slides were dried in air for 15min, rehydrated with
PBS for 5min, blocked for 30min with 1% bovine serum
albumin and 0.5% Tween 20 in PBS and washed three
times with PBS. Antibodies were diluted in blocking
buﬀer and incubated on the slides for 1h, and then
washed three times with PBS. Slides were incubated in
1.5mg/ml DAPI for 15min, the solution was aspirated
and coverslips were mounted with Mowiol mount media.
Cells were visualized with a Zeiss ﬂuorescence microscope
with  63 or  100 objectives. The following antibodies
were used: rabbit anti-Topo IIa (Topogen) and mouse
anti-V5 (Invitrogen). The secondary antibodies used
were Alexa Fluor 555 labeled goat anti-rabbit IgG
(Invitrogen) and Alexa Fluor 488 labeled goat anti-
mouse IgG (Invitrogen). To obtain the relative DNA con-
tent of cells with immunoﬂuorescent co-localization of
Metnase and Topo IIa, Vision Assistant version 2.6
from National Instrument was used. This program digi-
tally searches for cells with speciﬁc pixel intensity, allow-
ing for cells to be grouped according to DAPI ﬂuorescent
intensity into bimodal Go/G1 and G2/M peaks, with S
phase cells having intensities in between. At least 300
cells were digitally quantiﬁed for each population, and a
one-tailed Student’s t-test was used to assess diﬀerences in
the cell cycle phase populations.
Plasmid cleavage and kinetoplast DNA decatenation
The vector pFlag-Metnase was stably transfected into
HEK-293 cells, and Metnase was puriﬁed from lysates
using anti-FLAG beads followed by elution from a
Heparin-Sepharose 6 Fast Flow column (Amersham
Biosciences, Piscataway, NJ). Silver staining showed no
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Topo IIa (GE Healthcare) and catenated kinetoplast
DNA (kDNA; Topogen) were used according to the man-
ufacturer’s instructions. For plasmid DNA cleavage,
50ng/ml of plasmid pAdTrack (chosen for its large size)
was incubated with various Metnase concentrations at
378C for 60min in fresh 25mM Tris–HCl (pH 7.5),
5mM MnCl2 and 1mM dithiothreitol (DTT), and the
products were analyzed by 1% agarose gel electrophoresis.
kDNA are catenated minicircles that can be used as an
in vitro substrate for decatenation experiments (23,24).
Buﬀer and kDNA from the DNA Gyrase Assay kit
(Topogen) were used to assess kDNA decatenation.
Metnase is much less active in Mg
2+ than in Mn
2+, but
Topo IIa is not active in Mn
2+. At the MgCl2 concentra-
tion in this kit (8mM), there is no measurable Metnase
nuclease activity. kDNA (200ng/ml) was incubated in the
manufacturer’s buﬀer with increasing concentrations of
Metnase and/or Topo IIa for 4h at 378C per the manu-
facturer’s instructions and then analyzed by 1% agarose
gel electrophoresis. When Metnase was tested alone for its
eﬀect on kDNA, MnCl2 at 10mM replaced the MgCl2.
Each experiment was performed at least three times,
with densitometric analysis, and averages and SD are
shown.
Nuclear extracts
Nuclear extracts were prepared as we described (25) from
HEK-293T cells transduced with pcDNA-Metnase or
empty vector control. A ﬁnal 4-h dialysis step in 50mM
Tris–HCl (pH 8.0), 120mM KCl, 20mM MgCl2, 10%
glycerol and 0.5mM DTT at 48C was included to reduce
the salt concentration. This buﬀer was also used in
the kDNA decatenation assays with nuclear extracts.
Each experiment was performed at least three times,
with densitometric analysis, and averages and SD are
shown.
Mass spectroscopy
Samples were digested with trypsin (Sequencing Grade
Modiﬁed from Promega, Madison, WI) overnight. The
digested peptides were extracted and placed in ZipTip pip-
ette tips (Millipore) containing C18 reverse-phase media
to concentrate and purify peptides. Samples were spotted
on a MALDI plate, and peptide mass ﬁngerprinting was
done in MS mode on the Applied Biosystems 4700
MALDI Tof-Tof. The peptides were identiﬁed by search-
ing the peptide masses against the National Center for
Biotechnology Information and the Swissprot databases.
Results were conﬁrmed by sequencing the tryptic peptides
in MS/MS mode and using the database-searching algo-
rithm MASCOT to match the amino acid m/z. Each
experiment was performed twice with independent lots
of Metnase and Topo IIa.
RESULTS
Metnase interacts withTopo IIa
Since Topo IIa is the critical decatenating enzyme, the
physical interaction between Metnase and Topo IIa was
ﬁrst investigated using co-immunoprecipitation assays.
In reciprocal co-immunoprecipitation experiments
shown in Figure 1A, Topo IIa was detected in Metnase
immunoprecipitates, and Metnase was present in Topo IIa
immunoprecipitates. Using anti-sera against native
Metnase (5), endogenous Metnase was also found to be
present in Topo IIa immunoprecipitates (Figure 1B).
Figure 1. Physical interaction between Metnase and Topo IIa.( A) V5-tagged and endogenous Metnase immunoprecipitated (IP) from HEK-293 cells
co-immunoprecipitates Topo IIa, detected by western blotting. PCD, expression vector control; NS, non-speciﬁc anti-sera. (B) The Topo IIa inhibitor
ICRF-193 does not block the interaction between either endogenous or transduced Metnase and Topo IIa.( C) Immunoﬂuorescence co-localization
of Metnase (green) with Topo IIa (red) during chromosome condensation indicated by orange color in merged photomicrograph. (D) Co-localization
is maximal in G2/M cells on condensed chromosomes.
5824 Nucleic Acids Research, 2008, Vol. 36, No. 18This co-immunoprecipitation was observed in the presence
of DNase I, indicating that Metnase and Topo IIa interact
independently of DNA. The presence of ICRF-193 did not
delete the cellular interaction between Topo IIa and
Metnase (Figure 1B). By western analysis using synchro-
nized cells, Metnase expression is nearly equivalent in all
phases of the cell cycle (not shown).
Next, we examined Metnase and Topo IIa intracellular
co-localization using immunoﬂuorescence microscopy.
This analysis revealed that Metnase and Topo IIa fre-
quently co-localize, and co-localization was particularly
strong on condensed chromosomes (Figure 1C). When
cells were segregated by DNA content, there was a
2-fold greater co-localization of Metnase and Topo IIa
in G2/M cells than in G1 or S phase cells (Figure 1D).
Metnase promotes progression through themetaphase
decatenation checkpoint
The decatenation checkpoints can be triggered by expo-
sure to ICRF-193, which blocks Topo IIa function with-
out damaging DNA and therefore does not activate the
G2/M DNA damage checkpoint (11–17). Progression
through the metaphase decatenation checkpoint, the last
point at which chromatids can decatenate before aberrant
separation, was analyzed by measuring the percentage of
cells arrested in metaphase by ICRF-193. Increases in the
percentage of ICRF-193-induced metaphase cells reﬂect
arrest at the metaphase decatenation checkpoint. We
examined HEK-293 cells expressing normal, 3-fold
increased or 5-fold decreased levels of Metnase
(Figure 2A), after treatment with ICRF-193, VP-16 or
vehicle control (Figure 2B and C). HEK-293 cells express
moderate levels of both Topo IIa and Metnase and typi-
cally display an attenuated metaphase decatenation check-
point. These cells were chosen because they provide
enhanced sensitivity for detecting increased decatenation
checkpoint arrest with Metnase under-expression. Most
cell types express Metnase (5), but HEK-293T cells do
not express Metnase at detectable levels, perhaps due to
their transformation with T antigen (Figure 2A, 24). They
have an intact metaphase decatenation checkpoint, which
allowed us to analyze the decatenation checkpoint in
matched cells that either express or do not express
Metnase.
When cells were treated with ICRF-193, the percentage
of cells arrested in metaphase was inversely proportional
to Metnase levels. Thus, Metnase expression in HEK-
293T cells resulted in a 3-fold decrease in metaphase
cells compared to vector controls after a 4-h ICRF-193
treatment, and a 2.5-fold decrease after an 18-h treatment.
Reducing Metnase expression in HEK-293 cells resulted in
a 12-fold increase in metaphase cells after ICRF-193 expo-
sure compared to control cells, and increasing Metnase
expression in HEK-293 cells resulted in a 5-fold decrease
in the percentage of metaphase cells. We also observed
that ICRF-193 treatment yields a signiﬁcantly higher per-
centage of metaphase cells in untransduced HEK-293T
cells, which lack Metnase, compared to untransduced
HEK-293 cells, which express moderate levels of
Metnase. Thus, resistance to ICRF-193-induced
metaphase arrest correlates with Metnase expression
level. Interestingly, increased Metnase also reduced meta-
phase arrest induced by VP-16 (Figure 2B and C),
although such an arrest could also occur from DSBs.
Metnase over-expression allowed cells to continue to pro-
liferate in the presence of cytotoxic concentrations of VP-
16 by 4-fold (Figure 2D). In addition, Metnase over-
expression promoted proliferation in the presence of
ICRF-193 by 2-fold (Figure 2D).
We conﬁrmed the eﬀects of Metnase expression on pro-
gression through the decatenation checkpoints by analyz-
ing cell cycle proﬁles in the presence or absence of
ICRF-193 using ﬂow cytometry. This measures both
G2/M and metaphase decatenation checkpoints (15).
When HEK-293T cells were treated for 4h with 10mM
ICRF-193, the increase in the G2/M fraction was
13.5-fold higher in control cells compared to cells trans-
fected with a Metnase expression vector (Figure 2E). After
an 18-h treatment with ICRF-193, the diﬀerence between
control and Metnase-expressing cells was smaller, but
there were still signiﬁcantly less cells arrested in G2/M
with increased Metnase levels (Figure 2E). Based on
these in vivo data, we proposed that increased expression
of Metnase enhances Topo IIa activity, increasing the eﬃ-
ciency of chromosome decatenation and thereby inhibit-
ing initiation of the decatenation checkpoint arrest.
Metnaseenhances Topo IIadecatenation activity
To understand the molecular mechanism by which
Metnase promotes decatenation, we characterized the
activity of puriﬁed Metnase on supercoiled and catenated
DNA in vitro. Metnase converts supercoiled plasmid to
nicked, relaxed and linear forms, but does not further
degrade DNA (Figure 3A), as we showed previously (9).
We next examined the activity of Metnase on catenated
kDNA, which is composed of interlocked DNA minicir-
cles (25,26). As shown in Figure 3B, Metnase converts
catenated kDNA into mostly linear DNA and a smaller
amount of free, nicked, open circular DNA. In contrast,
Topo IIa converts kDNA into fully decatenated, relaxed,
covalently closed circular DNA (Figure 3C).
Since Metnase both interacts with Topo IIa and pos-
sesses catenated DNA cleavage activity, we next tested
whether Metnase and Topo IIa might function together
in decatenating kDNA. At concentrations of Metnase and
Topo IIa where neither protein had appreciable activity
on kDNA, they synergistically decatenated kDNA into
nicked and relaxed fully decatenated circular forms
(Figure 3C and D). Averaging multiple experiments,
there was more than a 6-fold increase in decatenation
when Metnase was added to limiting amounts of Topo
IIa (Figure 3D). The presence of ICRF-193 slightly
reduced the enhancement of kDNA decatenation by
Metnase, but that enhancement was still signiﬁcant
(Figure 3E and F). There was still more than a 4-fold
enhancement of decatenation with added Metnase.
However, when the nuclease activity of Metnase is deleted
by mutating a required amino acid [D483A, ref. (9)]
Metnase loses much but not all of its ability to enhance
Topo IIa (Figure 3G and H).
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tion is due to nonspeciﬁc Metnase nuclease activity, we
analyzed kDNA decatenation by Topo IIa in the presence
or absence of DNase I. In contrast to Metnase, DNase I
did not enhance Topo IIa decatenation to circular forms,
but it did produce linear DNA, which over time was
degraded (Figure 3I). Indeed, the presence of DNase I
inhibited Topo IIa decatenation activity.
Figure 2. Metnase promotes progression through the metaphase decatenation checkpoint. (A) Manipulated Metnase levels in HEK-293 and HEK-
293T cells examined using western analysis with anti-Metnase antibody and RT–PCR as described (5). b-Actin and 18S rRNA served as loading
controls for western blots and RT–PCR, respectively. HEK-293, but not HEK-293T, cells express endogenous Metnase. Stable Metnase over-
expression was achieved in HEK-293 cells transfected with pCD-Metnase, and HEK-293T cells transfected with pCAPP-Metnase; siMetnase
indicates stably transfected siRNA Metnase knockdown in HEK-293. (B) Decatenation checkpoint arrest induced by ICRF-193 was monitored
by the increase in metaphase cells using immunoﬂuorescence microscopy of cells stained with anti-tubulin antibodies (green) and DAPI (blue). pCD-
vector control, U6-siRNA control. (C) Quantitative analysis of ICRF-193 or VP-16 induces mitotic checkpoint arrest after subtraction of vehicle
controls. (D) HEK-293T cells stably transfected with pCAPP-Metnase or empty vector were seeded in medium with or without 0.5mM ICRF-193 on
Day 0 and counted daily. HEK-293T cells stably transfected with pCAPP-Metnase or empty vector were seeded in medium with or without 5mM
VP-16 on Day 0 and counted daily thereafter. (E) Flow cytometric analysis of G2/M fractions in HEK-293T cells stably transfected with empty or
Metnase expression vectors after 10mM ICRF-193 treatment.
5826 Nucleic Acids Research, 2008, Vol. 36, No. 18To further investigate the potentiation of Topo IIa dec-
atenation by Metnase, we tested the eﬀect of Metnase on
kDNA decatenation with nuclear extracts from HEK-
293T cells, which do not express Metnase, and a derivative
stably transfected with a Metnase expression vector. As
shown in Figure 4A, nuclear extracts from cells expressing
Metnase were signiﬁcantly more eﬀective at decatenating
kDNA than HEK-293T extracts, although the Topo IIa
levels were unchanged by over-expression of Metnase
(Figure 4B). This eﬀect was Metnase speciﬁc because the
decatenation activity of Metnase-containing extracts was
reduced by anti-Metnase antibodies (Figure 4C). Thus,
Metnase levels in nuclear extracts correlated with the
ability of these extracts to decatenate kDNA. We then
Figure 3. Metnase promotes Topo-IIa-mediated decatenation of kDNA. (A) Puriﬁed recombinant Metnase nicks supercoiled plasmid to relaxed,
open circular and linearized plasmid but does not degrade it. (B) Puriﬁed Metnase decatenates kDNA, forming linear DNA and a smaller amount of
nicked, open circular DNA. M1, M2-markers for kDNA forms as indicated. (C) Puriﬁed Metnase enhances Topo IIa decatenation of kDNA,
forming relaxed closed circular DNA. At concentrations of Metnase and Topo IIa where neither alone has an appreciable decatenation activity, they
act synergistically to decatenate kDNA to nicked open circular and relaxed closed circular DNA. (D) Graph of dose–response of the enhancement of
Topo IIa decatenation by Metnase. Densitometric analysis of open circular and closed circular versus well kDNA for relative kDNA decatenation
from n=3, SD too small for symbols. (E) ICRF-193 does not abrogate Metnase enhancement of Topo IIa decatenation. (F) Graph of densitometric
scans of kDNA decatenation performed in the presence of ICRF-193 shown in E, n=3, SD too small for symbols. (G) Metnase lacking nuclease
activity [D483A, ref. 9)] loses most but not all of its ability to enhance Topo IIa decatenation. (H) Graph of densitometry from three D483A
experiments, SD shown where larger than symbol. (I) DNase I nicks, linearizes and ultimately degrades kDNA, as opposed to Metnase activity in B.
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extracts with and without Metnase. Metnase-containing
extracts decatenated kDNA at a 3-fold higher rate than
HEK-293T control extracts (Figure 4C and D). As a con-
trol, decatenation with these nuclear extracts was exam-
ined in the presence of an irrelevant antibody. Anti-sera
against the Prh homeobox protein used as a control did
not abrogate the Metnase-mediated enhancement of dec-
atenation (Figure 4C). These data indicate that although
Topo IIa is capable of decatenating DNA in the absence
of Metnase, Metnase signiﬁcantly increases the reaction
rate.
Metnaseautomethylation preventspotentiation of Topo IIa-
mediated decatenation
SET domain proteins were originally deﬁned as histone
methylases, but they also methylate other proteins, includ-
ing themselves and transcription factors (26–28). We,
therefore, investigated whether decatenation could be
regulated by the histone methylase activity of Metnase.
It was possible that Metnase could methylate itself or
Topo IIa, modifying its synergistic eﬀect on decatenation.
S-Adenosyl methionine (SAM) is the primary cellular
methyl donor, and we tested whether SAM inﬂuenced
Metnase potentiation of Topo IIa-mediated decatenation.
Interestingly, SAM fully abrogated the eﬀect of Metnase
on decatenation (Figure 5A and B). SAM had no eﬀect on
decatenation by Topo IIa alone, indicating that the abro-
gation of Metnase potentiation of Topo IIa activity is
Metnase dependent. S-Adenosyl homocysteine (SAH) is
a pseudo-methyl donor that binds to methyltransferase
active sites but cannot donate a methyl group. SAH had
no eﬀect on the Metnase potentiation of Topo IIa
decatenation activity (nor did it aﬀect Topo IIa activity
alone) (Figure 5A and B), indicating that the SAM abro-
gation of decatenation with Metnase depends on methyl
transfer. When SAM and SAH were both present, deca-
tenation by Metnase and Topo IIa partially reduced, indi-
cating that SAH competes with SAM to prevent
methylation. However, SAM did not alter the nuclease
activity of Metnase (Figure 5C).
The reduction of decatenation by SAM could reﬂect
Metnase automethylation, or methylation of Topo IIa.
Therefore, we performed MALDI Tof-Tof mass spectro-
scopy on Metnase and Topo IIa individually and together
in the presence or absence of SAM. We found no evidence
of Topo IIa methylation (data not shown), but in the
presence of SAM, Metnase was automethylated at several
positions. The strongest signal was monomethylation of
K485, with an average of 86% of lysine residues methy-
lated at this position (Figure 5D). Methylation of three
other arginine and lysine residues was also apparent
(R223, R469 and K122), but <25% of these residues
were methylated (data not shown). These results suggest
that Metnase automethylation regulates its ability to
potentiate Topo IIa-dependent decatenation. We next
asked whether methylated Metnase exists intracellularly.
We found that Metnase immunoprecipitated from HEK-
293 cells was recognized by anti-methyl lysine antibodies
on western analysis (Figure 5D).
DISCUSSION
We showed previously that Metnase methylates histone
H3 K36 and promotes DSB repair by NHEJ (5). Others
have shown that Metnase has partial transposase activity
Figure 4. Decatenation of kDNA by nuclear extracts is enhanced by Metnase. (A) kDNA was treated with nuclear extracts from HEK-293T cells
transfected with empty vector (control extracts) or derivatives stably transfected with a Metnase expression vector (Metnase extracts). Reactions
containing anti-sera against Metnase show signiﬁcantly reduced decatenation. (B) Topo IIa levels were similar in the two cell lines by western
analysis, while Metnase was present only in the transfected line. (C) Time course of kDNA decatenation with and without Metnase. An antibody
against the homeobox gene Prh did not inhibit Metnase-mediated decatenation as did the antibody against Metnase. (D) Graph of time course of
kDNA decatenation reactions catalyzed by nuclear extracts, average of three experiments.
5828 Nucleic Acids Research, 2008, Vol. 36, No. 18and is only present in primates (6–8). We now show that
Metnase interacts with Topo IIa, these proteins co-localize
in vivo and Metnase enhances Topo IIa decatenation. This
interaction was independent of DNA. We also found that
Metnase levels regulate initiation of metaphase decatena-
tion checkpoint arrest. Cells with increased levels of
Metnase show attenuated decatenation checkpoint arrest
compared to cells with lower levels of Metnase. Over-
expression of Metnase compensates for ICRF-193 and
VP-16 inhibition of Topo IIa, preventing engagement of
this checkpoint. Based on these in vivo data, we propose
that increased expression of Metnase enhances Topo IIa
activity, increasing the eﬃciency of chromosome decatena-
tion and inhibiting initiation of decatenation checkpoint
arrest. Cancer cells also show attenuated decatenation
checkpoints when Topo IIa is inhibited by ICRF-193
(11–17). It is possible that the resistance to ICRF-193 in
these cells is partially mediated by robust Metnase levels.
VP-16 promotes cell cycle arrest by inhibiting Topo IIa
function following its DNA cleavage step, and this DNA-
damage-induced arrest is distinct from the decatenation
checkpoint (11–17). However, VP-16 also triggers decate-
nation checkpoint arrest by inhibiting Topo IIa, although
the decatenation arrest is often overshadowed by the
DNA damage checkpoint. We show here that increasing
Metnase levels overcomes VP-16 eﬀects on metaphase
arrest and on cell proliferation. This could result from
Metnase potentiation of Topo IIa decatenation and/or
DSB repair by NHEJ. The increase in proliferation with
Metnase over-expression in the presence of VP-16 is
greater than in the presence of ICRF-193. It is likely
that this increase is due to the additive DNA repair com-
ponent of Metnase on VP-16-induced DNA damage,
which does not occur with ICRF-193. Alternatively, it is
also possible that Metnase blocks VP-16 (and ICRF-193)
access to Topo IIa. Regardless, these results suggest that
Metnase is an important mediator of resistance to VP-16
used in treating human malignancies. It is also noteworthy
that the Metnase gene is located at 3p26, which shows
frequent abnormalities in multiple cancers including
acute and chronic lymphocytic leukemia, breast cancer,
hereditary prostate cancer, myeloma, myelodysplasia
and non-Hodgkin’s lymphoma (5). It is possible that the
cancer-associated 3p26 abnormalities alter the function or
expression of Metnase.
The in vivo observations implicating Metnase in pro-
moting Topo-IIa-mediated chromosome decatenation
are supported by in vitro analyses with puriﬁed proteins.
Although Topo IIa alone can fully decatenate kDNA,
Metnase greatly enhances this activity. The results with
puriﬁed proteins are also consistent with the nuclear
extract studies, which showed enhanced decatenation
when Metnase levels were increased. The enhancement
of decatenation by Metnase is not a result of nonspeciﬁc
nuclease activity because DNase I did not promote Topo
IIa decatenation activity. The nuclease activity of Metnase
is important for its enhancement of decatenation, as delet-
ing that activity (9) markedly decreases its Topo IIa
enhancement. However, there is still some enhancement
remaining, and Metnase can still enhance Topo IIa dec-
atenation in buﬀers and at levels where there is little nucle-
ase function seen. Thus, Metnase may also function as a
structural co-factor to increase Topo IIa activity. This
model is consistent with the known mechanism of Topo
IIa, as DNA cleavage, strand passage and religation are
catalyzed by Topo IIa in a coordinated set of covalent
reactions (10).
Metnase may promote Topo IIa activity in a manner
analogous to extra-cellular signal-related kinase (ERK2).
ERK2 promotes Topo IIa activity, and this was initially
Figure 5. SAM blocks the Metnase potentiation of Topo IIa decatena-
tion. (A) kDNA decatenation assays performed as in Figure 4 in the
presence or absence of the methyl donor SAM or non-donating SAM
analog, SAH (2mM each, except 1mM each when both were present).
(B) Plot of decatenation with 0.25–1U of Topo IIa, 200ng Metnase,
2mM SAM or SAH based on densitometric scans of gels as in A.
Shown are averages for three experiments, with all values normalized
to 1U of Topo IIa (control=100%). Statistics calculated by t-tests.
(C) SAM (2mM) does not aﬀect the Metnase nuclease activity toward
the kDNA substrate. Metnase was present at 0, 100 or 200ng indicated
by triangles. Metnase is automethylated at residue K485. (D) MALDI
tof-tof mass spectrum of Metnase alone, showing the unmodiﬁed K485
peptide at m/z of 979.4849 as predicted. Mass spectrum of Metnase
incubated with SAM in methylase buﬀer showing methylation of the
K485 peptide at m/z of 993.5866. Metnase immunoprecipitated from
HEK-293 cells has metylated lysines. Methylated Metnase is present
intracellularly, by western analysis.
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indeed phosphorylate Topo IIa in vitro. However, this
phosphorylation is not required to enhance Topo IIa
activity as kinase-inactive ERK2 also stimulates Topo
IIa (29). ERK2, therefore, functions as a structural co-
factor for Topo IIa activity in vitro. This is also similar
to HMGB1 interacting with Topo IIa to enhance its DNA
binding and its decatenation activity in vitro (30). This
mechanism is in contrast to BRCA1, which may activate
Topo IIa by ubiquitylation (31).
Besides Metnase, only BRCA1 has been demonstrated
to regulate the in vivo decatenation checkpoint response.
Topo IIa exists in a large complex termed the toposome,
and components of this complex may regulate Topo IIa
function (32,33). Metnase promotes both decatenation
and NHEJ, and its varied activities could be regulated
by its presence or absence in the toposome. For example,
Metnase recruitment to DNA damage sites could deplete
it from the toposome, and this could reduce Topo IIa
activity, slowing decatenation and cell cycle progression,
thereby increasing time for repair before mitosis. We
recently reported that Metnase interaction with the DNA
repair component Pso4 is induced by DNA damage and is
importantfortheabilityofMetnasetoenhanceNHEJ(34).
It is possible that Metnase is sequestered with Pso4 after
DNA damage, which might preclude it from Topo IIa
interaction, and thus slowing decatenation.
There is another example of an SET domain protein
regulated by automethylation. G9a negatively regulates
its histone methylation activity by automethylation
(27,28). Metnase methylates histone H3 in vitro (5), and
we show here that Metnase is strongly automethylated on
K485 and weakly automethylated at three other residues.
Metnase does not appear to methylate Topo IIa, but SAM
blocks Metnase potentiation of Topo IIa decatenation. If
SAM binding to the Metnase methyltransferase active site
inhibited the Metnase–Topo IIa interaction, then SAH
would be expected to produce the same eﬀect, but this
was not observed. Metnase potentiation of Topo IIa
decatenation is inhibited by SAM, and this requires the
donation of a methyl group to Metnase. Also, lysine-
methylated Metnase species exist intracellularly, as such
species could be immunoprecipitated. This represents a
novel function for an SET domain protein and suggests
a new regulatory mode for this important class of protein
post-translational modiﬁcation.
Metnase is widely expressed in human tissues and cell
lines (5), but three cell lines have been identiﬁed that do
not express Metnase, all of which are transformed by
SV40T-antigen, including the HEK-293T cells used here
(also the BPH and GM05849 lines). It is possible that
T-antigen represses Metnase expression, or that it func-
tionally replaces Metnase in some manner, selecting for
cells that do not express it.
The data here have general signiﬁcance for several rea-
sons. First, the precise biochemical process whereby repli-
cated chromosomes are untangled is not well understood,
but it is clear that Metnase enhances this process, perhaps
at an early, rate-limiting step of decatenation. Second, the
automethylation of Metnase is a unique feedback regula-
tory mechanism to slow down decatenation. It also shows
that SET domain protein automethylation can aﬀect other
functions besides histone methyltransferase activity, as
seen with G9a (27,28). Third, the ability of cells expressing
Metnase to continue to proliferate in the presence of lethal
concentrations of the clinically relevant Topo IIa inhibitor
VP-16 (Figure 2D) suggests a combination chemotherapy
strategy in which an inhibitor of Metnase would potenti-
ate the lethal eﬀects of topoisomerase inhibitors on human
cancer. Finally, since transposase activity would be deleter-
ioustohumans,thebeneﬁtofatransposasedomainprotein
in humans has not been deﬁned (6,9,35). However, these
data demonstrate such a beneﬁt, and perhaps shed light on
how Metnase was selected for in primates.
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